MNOV
Medicinova Inc

4,613
Mkt Cap
$70.14M
Volume
15,240.00
52W High
$2.48
52W Low
$1.13
PE Ratio
-5.84
MNOV Fundamentals
Price
$1.43
Prev Close
$1.43
Open
$1.43
50D MA
$1.31
Beta
0.61
Avg. Volume
2.35M
EPS (Annual)
-$0.2253
P/B
1.60
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
MediciNova (NASDAQ:MNOV) Issues Earnings Results, Beats Estimates By $0.02 EPS
MediciNova (NASDAQ:MNOV - Get Free Report) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’
Stocktwits·21d ago
News Placeholder
10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday
Earnings largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.
Stocktwits·1y ago
News Placeholder
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com
StockNews.com initiated coverage on shares of MediciNova (NASDAQ:MNOV - Free Report) in a report published on Friday morning. The brokerage issued a hold rating on the biopharmaceutical company's...
Ticker Report·2y ago
News Placeholder
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...
Globe Newswire·2y ago
News Placeholder
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
LA JOLLA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...
Globe Newswire·2y ago
News Placeholder
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
LA JOLLA, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...
Globe Newswire·2y ago
News Placeholder
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)
StockNews.com started coverage on shares of MediciNova (NASDAQ:MNOV Free Report) in a report released on Tuesday. The brokerage issued a hold rating on the biopharmaceutical companys...
Ticker Report·2y ago
News Placeholder
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com
StockNews.com started coverage on shares of MediciNova (NASDAQ:MNOV Free Report) in a research report released on Tuesday. The firm issued a hold rating on the biopharmaceutical...
Zolmax·2y ago
News Placeholder
MediciNova's MN-166 shows efficacy in lung injury study
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago

Latest MNOV News

View

Advertisement|Remove ads.

Advertisement|Remove ads.